Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;100(10):1311-1317.
doi: 10.1038/s41374-020-0424-5. Epub 2020 Apr 6.

Digital quantitative assessment of PD-L1 using digital spatial profiling

Affiliations

Digital quantitative assessment of PD-L1 using digital spatial profiling

Swati Gupta et al. Lab Invest. 2020 Oct.

Abstract

The assessment of programmed death 1 ligand 1 (PD-L1) expression by Immunohistochemistry (IHC) is the US Food and Drug Administration (FDA)-approved predictive marker to select responders to checkpoint blockade anti-PD-1/PD-L1 axis immunotherapies. Different PD-L1 immunohistochemistry (IHC) assays use different antibodies and different scoring methods in tumor cells and immune cells. Multiple studies have compared the performance of these assays with variable results. Here, we investigate an alternative method for assessment of PD-L1 using a new technology known as digital spatial profiling. We use a previously described standardization tissue microarray (TMA) to assess the accuracy of the method and compare digital spatial profiler (DSP) to each FDA-approved PD-L1 assays, one LDT assay and three quantitative fluorescence assays. The standardized cell line Index tissue microarray contains 10 isogenic cells lines in triplicates expressing various ranges of PD-L1. The dynamic range of PD-L1 digital counts was measured in the ten cell lines on the Index TMA using the GeoMx DSP assay and read on the nCounter platform. The digital method shows very high correlation with immunohistochemistry scored with quantitative software and with quantitative fluorescence. High correlation of PD-L1 digital DSP counts were seen between rows on the same Index TMA. Finally, experiments from two Index TMAs showed reproducibility of DSP counts were independent of variable slide storage time over a three-week period after antibody labeling but before collection of cleaved tags. In summary, DSP appears to have quantitative potential comparable to quantitative immunohistochemistry. It is possible that this technology could be used as a PD-L1 protein measurement system for companion diagnostic testing for immune therapy.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

DLR is a consultant/advisor to Amgen, Astra Zeneca, Agendia, Biocept, Biocept, BMS, Cell Signaling Technology, Cepheid, Daiichi Sankyo, GSK, InVicro/Konica Minolta, Lilly, Merck, Perkin Elmer, PAIGE.AI, Sanofi and Ultivue. KF is an employee of Nanostring. The remaining authors declare no competing interests.

Figures

Figure 1:
Figure 1:. Index TMA layout for PD-L1 quantification.
(A) Schematic map along with ten standardized cell line codes and (B) representative image of the stained standardized TMA and 300um diameter ROIs as white circles.
Figure 2:
Figure 2:. Overview of Experimental Plan.
Three standardized TMA were stained with Human IO panel and nuclear stain. First two experiments were stained and collected in the same week. Third experiment was stained and each row was collected one week apart.
Figure 3:
Figure 3:. Correlation of Log2 transformed PD-L1 data from GeoMx DSP, QIF and IHC DAB.
Regression of PD-L1 protein expression by DSP with (A-C) QIF assay performed using 3 antibodies (E1L3N, SP142, and SP263) and (D-H) IHC DAB assay performed using 5 antibodies (E1L3N, SP142, SP263, 22C3 and 28–8). Each dot represents average of 2 TMAs (GeoMx DSP), 3 TMAs (QIF) and 20 TMAs (IHC DAB) with 3 pellet per cell clone in one TMA.
Figure 4:
Figure 4:. Reproducibility across rows and experiments stained and collected in the same week.
Bar graph show (A) signal to noise ratio and (B) PD-L1 counts for three rows from same experiment. Regression on Log2 scale for PD-L1 counts (C) between two rows from same experiment and (D) average PD-L1 counts of three rows between two experiments.
Figure 5:
Figure 5:. Reproducibility across rows collected one week apart from same staining.
(A) Distribution of PD-L1, Histone H3 and average IC raw counts from all cell pellet collected one week apart. Bar graph show (B) signal to noise ratio and (C) PD-L1 counts for three rows. Regression on Log2 scale for PD-L1 counts (D-E) between two rows collected on different weeks.

References

    1. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017;377(20):1919–29. - PubMed
    1. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387(10027):1540–50. - PubMed
    1. Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, et al. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol 2017;35(35):3924–33. - PMC - PubMed
    1. McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, et al. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. J Clin Oncol 2016;34(8):833–42. - PubMed
    1. Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther 2015;14(4):847–56. - PubMed

Publication types

MeSH terms